What are the key differences in mechanism between Lazertinib and Osimertinib?

Lazertinib (Lazertinib) and Osimertinib (Osimertinib) are both third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EG FR-TKI), is widely used in the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC). Although both drugs belong to the same generation and both target EGFR kinase mutations, there are some key differences in molecular structure, selectivity, target spectrum and clinical application details. These differences have an important impact on the efficacy, safety and applicable patient groups of the drugs.

First of all, from the perspective of mechanism of action and target selectivity, osimertinib is an irreversible inhibitor specifically designed to deal with EGFR T790M resistance mutations. It forms a covalent bond with the C797 site of EGFR and inhibits EGFR kinase activity, thereby blocking signal transduction and inhibiting tumor cell proliferation. Osimertinib is effective in inhibiting EGFR activating mutations (such as Del19 and L858R) and drug-resistant mutation T790M showed high efficacy, while the inhibition of wild-type EGFR was relatively weak, reducing side effects such as rash.

As a third-generation EGFR inhibitor developed subsequently, Lanzertinib, in addition to targeting classic activating mutations and T790M mutations, also shows certain inhibitory activity against the EGFR C797S mutation, one of the key mutations for osimertinib resistance. The molecular structure of lanzetinib has been optimized to make it have stronger binding ability to different EGFR variants and better brain penetration, which is particularly important for the prevention and treatment of lung cancer patients with brain metastasis. In addition, lanzetinib has high selectivity and can effectively distinguish EGFR mutant and wild-type, which can theoretically reduce the toxic and side effects of normal tissues.

Secondly, in terms of clinical efficacy, osimertinib, as the first approved third-generation EGFR-TKI, significantly prolongs the survival of late-stage EGFR by virtue of its efficient inhibition of T790M mutation.The progression-free survival (PFS) and overall survival (OS) of patients with mutated lung cancer are widely used as first-line and post-resistance treatment options. It also shows good efficacy in patients with brain metastases and has become an important treatment option for patients with lung cancer.

Although lanzatinib entered clinical practice late, its clinical research data shows that it has better drug distribution and efficacy in patients with brain metastases, and may provide new treatment ideas for the C797S mutation. Some clinical data also show that lanzetinib delays the emergence of drug resistance in some patients and is well tolerated and safe. In the future, as more clinical trial data accumulates, lanzitinib is expected to become an important supplement or alternative to osimertinib.

Furthermore, in terms of safety and tolerability, osimertinib has relatively good overall tolerability due to its less inhibitory effect on wild-type EGFR. Common side effects include dry skin, diarrhea and mild liver function abnormalities. Lanzitinib also shows good safety, and due to its strong selectivity and brain penetration, it may cause fewer central nervous system-related side effects, but the specific safety differences still need to be verified by more large-scale studies.

Finally, there are differences in the scope of drug use and treatment strategies. Osimertinib has been approved by regulatory authorities in many countries as a first-line treatment for EGFRmutatedNSCLC and as a standard treatment for patients with T790M resistance. Lanzitinib is mainly in the accelerated approval stage or clinical trials, and is expected to provide more effective treatment options for patients with more complex resistance mechanisms (such as C797S) and brain metastases in the future. In addition, the potential of lanzatinib in drug combination therapy or sequential therapy has also attracted much attention.

In summary, lanzutinib and osimertinib, as third-generation EGFR inhibitors, both inhibit EGFR activating mutations and drug-resistant mutations are the core, but Lanzertinib has certain activity against the C797S mutation in terms of molecular design, and has better brain penetration, which may lead to a wider range of therapeutic applications. With mature clinical evidence and a wide range of applicable populations, osimertinib remains the cornerstone of the current treatment of EGFR mutated lung cancer. In the future, as new data and new indications continue to emerge, the two will play complementary and synergistic roles in the precision treatment of lung cancer, bringing more treatment hope to patients.

Reference materials:https://www.drugs.com/donanemab.html